Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis

Zhi‐Feng Miao(Kaohsiung Medical University), Jinyu Huang(Soochow University), Yingying Xu(Wannan Medical College), Tingting Zhao(Sun Yat-sen University), Huimian Xu(First Hospital of China Medical University), Xingyu Liu(Tongji Hospital), Yongxi Song(First Hospital of China Medical University), Hao Xu(China Medical University)
BMC Cancer
January 31, 2018
10.1186/s12885-018-4027-0
Cited by 58

Related Papers

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Biomarkers of aging
|Science China Life Sciences|2023|362
Microenvironment-Responsive Metal-Phenolic Nanozyme Release Platform with Antibacterial, ROS Scavenging, and Osteogenesis for Periodontitis
|ACS Nano|2023|345